- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
White House in Damage Control Over Obama Supreme Court Remarks
The White House
Barack Obama
healthcare reform
was forced on the defensive on Wednesday as it sought to explain controversial remarks President made earlier in the week about the Supreme Court's review of his signature law.
Jay Carney
"What he did was make an unremarkable observation about 80 years of Supreme Court history," White House spokesman told reporters during a White House briefing dominated by the topic.
Obama expressed confidence on Monday that the Court would not take an "unprecedented, extraordinary step" by overturning the law, provoking a storm of protest that he had been inaccurate and was challenging the nation's top judges in an election year.
Read the full story: http://hcp.lv/I6rIiL
Source: The Chicago Tribune
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
